Since the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
|
|
- Myron Jennings
- 5 years ago
- Views:
Transcription
1 2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D. 1,2 1 The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland. 2 Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland. BACKGROUND. The authors examined the cases of men who had undergone radical prostatectomy for low-volume clinical T1c prostate carcinoma that was judged to be insignificant on the basis of previously established preoperative clinicopathologic parameters. Pathologic findings subsequently were analyzed for correlations with extent of disease in an attempt to validate the contemporary usefulness of existing parameters for predicting the significance of prostate tumors. METHODS. A series of 237 men who had undergone radical prostatectomy for T1c disease between December 2000 and August 2003 was evaluated. Insignificant prostate carcinoma as assessed on biopsy was defined according to the 1994 Epstein criteria, which were as follows: prostate-specific antigen density 0.15 ng/ml, Gleason score 6, fewer than 3 cores containing prostate carcinoma, and 50% involvement of any core with prostate carcinoma. Postsurgical pathologic findings were analyzed for potential correlations with the Epstein criteria. RESULTS. According to the Epstein needle biopsy criteria, organ-confined prostate carcinoma was detected in 91.6% of all patients, whereas the remaining 8.4% of patients were found to have non-organ-confined disease. Comparison of pathologic findings and Epstein biopsy criteria revealed that alteration of the original criteria did not improve the detection of non-organ-confined prostate carcinoma. CONCLUSIONS. The findings made in the current study suggest that the majority of patients with T1c prostate carcinoma have insignificant disease. Furthermore, it was found that the Epstein criteria for identifying insignificant prostate carcinoma remained a useful tool in the making of treatment-related decisions. Cancer 2004; 101: American Cancer Society. KEYWORDS: prostate carcinoma, insignificant cancer, prostatectomy, prostatespecific antigen density. See editorial on pages , this issue. Supported by National Institutes of Health Specialized Programs of Research Excellence Grant P50CA Address for reprints: Alan Partin, M.D., Ph.D., The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, 600 North Wolfe Street, Jefferson Bldg., Room 157, Baltimore, MD 21287; Fax: (410) ; apartin@jhmi.edu Received July 7, 2004; accepted July 13, Since the beginning of the prostate-specific antigen (PSA) era in the early 1990s, an increasing number of cases of prostate carcinoma have been diagnosed solely on the basis of elevated PSA levels (T1c disease), rather than on the basis of suspicious findings on a digital rectal examination (T2 disease). 1,2 Because the prevalence of prostate carcinoma increased dramatically during the PSA era, clinicians feared that widespread PSA screening was leading to the detection of an unreasonable number of so-called clinically insignificant tumors and, in turn, to a marked increase in potentially unnecessary treatment. 3,4 Epstein et al. 5 developed PSA- and needle biopsy related criteria (namely, PSA density 0.15 ng/ml, the absence of adverse pathologic findings on biopsy [i.e., biopsy Gleason score 6], the presence of prostate carcinoma in fewer than 3 cores [from a 6-core biopsy 2004 American Cancer Society DOI /cncr Published online 15 September 2004 in Wiley InterScience (
2 2002 CANCER November 1, 2004 / Volume 101 / Number 9 sample], and the finding of no more than 50% prostate carcinoma involvement in any of these cores) for identifying insignificant prostate carcinoma. According to these criteria, in 1994, 79% of tumors with volume 0.5 cm 3 were organ confined and did not qualify as high-grade lesions at the time of radical prostatectomy. Among men who had undergone surgery and who had PSA density 0.15 ng/ml or any adverse findings on needle biopsy, 83% had tumors that were larger than 0.5 cm 3 in volume and/or non-organ-confined disease. There are several treatment options for patients with insignificant, small-volume prostate tumors; among these options are radical surgery, radiotherapy, and expectant management. Radical prostatectomy has proven to be an effective definitive treatment method, yielding excellent long-term results. 6,7 In the current study, we attempted to validate the 1994 Epstein criteria in a contemporary series ( ) by investigating whether these criteria (as assessed in pathologic specimens obtained from clinical T1c prostate tumors) continued to be indicative of small-volume, insignificant prostate carcinoma. MATERIALS AND METHODS The study population consisted of 237 men who had been diagnosed with clinical T1c prostate carcinoma. All participants had undergone anatomic radical retropubic prostatectomy with pelvic lymph node dissection at The Johns Hopkins Hospital (Baltimore, MD) between December 2000 and August Staging was performed according to the 1992 American Joint Committee on Cancer TNM system, with disease stages being based on tumor palpability. The initial PSA concentration was assessed before therapeutic intervention. Tissue samples obtained via transrectal ultrasound biopsy were graded according to the Gleason system. All patient data were reviewed retrospectively as part of an internal review board approved, Health Insurance Portability and Accountability Act compliant protocol, and informed consent was obtained prior to surgery. According to Epstein et al., 5 insignificant prostate carcinoma was defined by the following features: PSA density 0.15 ng/ml, biopsy Gleason score 6, the presence of disease in fewer than 3 biopsy cores, and 50% prostate carcinoma involvement in each of these cores. All prostate biopsy samples obtained at outside institutions were reviewed at The Johns Hopkins Hospital. PSA density was calculated by dividing the absolute PSA value by the prostatic weight, which was defined as the weight of the surgical specimen minus the weight of the seminal vesicles. Due to the large number of external referrals, data on prostatic volume as assessed by transrectal ultrasonography and on number of biopsies performed were not available for the entire study population. Surgical specimens were evaluated using the Gleason grading system. Extraprostatic extension, when present, was subclassified as being either focal or established. 8 In addition, using a previously described method, 9 surgical resection margins were designated as being positive or negative. Seminal vesicle involvement was considered to be present upon penetration of the tumor into the muscular coat of the seminal vesicle. RESULTS Table 1 summarizes the characteristics of the patient population, and Table 2 summarizes the pathologic findings made in these patients after radical retropubic prostatectomy. Organ-confined disease was found on radical prostatectomy in 217 patients (91.6%). In addition, 11 patients with non-organ-confined disease had PSA densities of ng/ml. Of these 11 patients, 6 had 1 positive biopsy core, and the remaining 5 had 2 positive biopsy cores. Overall, 10 patients with non-organ-confined disease had 1 biopsy core that was positive for malignancy, and another 10 had 2 cores that were positive for malignancy. Fifteen of the 20 patients with non-organ-confined disease had a maximum core involvement level of less than 30%, whereas 5 (25%) had a maximum involvement level of 30 50%. Alteration of any one of the original Epstein criteria did not change the accuracy with which nonorgan-confined disease could be predicted. Patients with extraprostatic extension, negative surgical margins, and no seminal vesicle or lymph node involvement (n 13) had a mean PSA density of 0.11 ng/ml (median, 0.12 ng/ml; standard deviation, 0.02 ng/ ml), a mean maximum of 19.6% involvement in positive biopsy cores (median, 15%; standard deviation, 12.33%), and a mean of 1.4 positive cores per patient (median, 1; standard deviation, 0.51). Among patients with extraprostatic extension, positive surgical margins, and no seminal vesicle or lymph node involvement (n 5), the mean PSA density was 0.13 ng/ml (median, 0.14 ng/ml; standard deviation, 0.02 ng/ ml), the mean maximum percentage of involvement in positive cores was 34% (median, 40%; standard deviation, 13.42%), and the mean number of positive cores per patient was 1.8 (median, 2; standard deviation, 0.45). In two specimens, involvement of the seminal vesicle was detected in the absence of lymph node involvement; the PSA densities recorded in these specimens were 0.07 ng/ml and 0.10 ng/ml, respectively. In one of these two cases, one core was found to be
3 Insignificant Prostate Carcinoma/Bastian et al TABLE 1 Patient Characteristics Characteristic No. of patients (%) a All patients 237 Age at surgery (yrs) Mean 56.8 Median 57 Range Preoperative PSA value (ng/ml) Mean 4.77 Median 4.5 Range PSA density (ng/ml) Mean 0.10 Median 0.09 Range Prostatic weight in surgical specimen (g) Mean 53 Median 45.5 Preoperative Gleason score (100) Postoperative Gleason score 5 1 (0.43) (89.87) 7 21 (8.86) 8 2 (0.84) Undergraded 23 (9.7) Overgraded 1 (0.43) Graded correctly 213 (89.87) No. of positive biopsy cores (67.09) 2 78 (32.91) Maximum percent involvement in positive cores 5% 24 (10.13) 10% 64 (27) 15% 17 (7.17) 20% 42 (17.72) 25% 8 (3.38) 30% 37 (15.61) 35 40% 25 (10.55) 45 50% 20 (8.44) PSA: prostate-specific antigen. a Unless otherwise indicated. TABLE 2 Pathologic Findings on Radical Prostatectomy Finding No. of patients (%) Organ-confined prostate carcinoma 217 (91.57) With positive SM 0 (0) Non-organ-confined prostate carcinoma 20 (8.43) With EPE, negative SM, no SV involvement, and negative LN 13 With EPE, positive SM, no SV involvement, and negative LN 5 With SV involvement and negative LN 2 With positive LN 0 Total 237 (100) EPE: extraprostatic extension; SM: surgical margins; SV: seminal vesicle; LN: lymph nodes. positive for malignancy, and in the other case, two cores were found to be positive; however, in both cases, the percent involvement per positive core was 30%. Of the 217 patients with organ-confined prostate carcinoma, 2 had Gleason Grade 8 tumors, and 16 had Gleason Grade 7 tumors. Five patients with findings of Gleason Grade 7 disease in their surgical specimens had non-organ-confined prostate carcinoma. With a maximum follow-up duration of less than 3 years, useful information regarding biochemical recurrence was not available for patients in the current cohort. DISCUSSION Patients diagnosed with clinical T1c disease can choose from a range of treatment options, including expectant management, radical retropubic prostatectomy, and various forms of radiotherapy. The established combination of independent predictors of prostate carcinoma significance may help to identify patients who are more likely to have non-organ-confined disease. Despite the commonly feared possibilities of overdetection and overtreatment, non-organconfined disease was detected in only 8.4% of the current cohort. Although the 1994 Epstein criteria were developed to identify potentially insignificant tumors at radical prostatectomy and thus to ascertain patients who are suited to undergo expectant therapy, these criteria also could be used to identify men for whom definitive therapy, with its excellent cure rate, would be appropriate. Using these criteria in the current series, 91.6% of tumors were correctly identified as organ-confined lesions, which can be cured with radical surgery. Although it might have been possible to manage many of these tumors with expectant therapy, some tumors, if left untreated over time, may have grown incurable before they became palpable, especially in younger men with relatively long life expectancies. In 17 patients with organ-confined prostate carcinoma, Gleason Grade 7 or 8 disease was detected in a surgical specimen. Due to complete prostate removal, such patients are likely to be cured; however, they continue to be at risk for biochemical recurrence and/or disease progression. 10,11 Despite the commonly used core method, it is possible for the dominant tumor to go undetected on needle biopsy. It has been demonstrated that the probability of detecting prostate carcinoma and the accuracy of pathologic grading both increase with increasing number of biopsy cores obtained. 12,13 The number of cores found to be positive for malignancy also varies according to the number of cores obtained, as does the probability of detecting an elevated level of involvement in a given positive core. When the Epstein criteria were developed, the standard technique
4 2004 CANCER November 1, 2004 / Volume 101 / Number 9 in use at The Johns Hopkins Hospital was a sextant (i.e., six-core) biopsy procedure. In contrast, the protocol currently favored at our institution (and increasingly throughout the United States) involves the acquisition of cores per patient. In the current study, when a tumor was detected by needle biopsy and fewer than 3 cores were found to be positive for malignancy, with each core exhibiting 50% tumor involvement, the number of cores obtained and the number of positive cores (1 or 2) did not affect the identification of insignificant tumors. Another parameter that plays a role in the prediction of tumor significance using the Epstein criteria is the maximum percent involvement in positive cores. A hypothetic reduction in this figure from 50% to 30% would have caused the number of patients identified as having organ-confined disease to decrease by 2.1% (n 5); however, alteration of the Epstein criteria with respect to this parameter alone did not lead to an increase in the rate of detection of non-organ-confined disease. Originally, the finding of a moderate prostate tumor was considered to be biologically significant. 5 Only 15% of all patients with such tumors, which typically are curable, were found to carry a risk of disease progression 10 years after radical prostatectomy. In the original model for identifying insignificant tumors, age, reason for evaluation, method of detection, and transrectal ultrasonography findings were not predictive of the extent of nonpalpable prostate carcinoma; instead, the best model for ascertaining insignificant tumors included PSA density, needle biopsy findings, and serum PSA level. 5 In the current study, no difference was noted when these parameters were altered; however, insignificant tumors were documented in 16% of the 157 patients in the original series examined by Epstein et al., 5 who concluded that a watchful waiting approach consisting of serial PSA measurements and repeated biopsies may be appropriate in such cases. It is noteworthy that even in the current series of insignificant tumors (as identified using the Epstein criteria), 8.4% of all cases were classified as nonorgan-confined disease. Due to complete tumor removal and the subsequent presence of negative surgical margins, 15 of the 20 patients with non-organconfined disease in the current study were likely to have been cured, with the probability of biochemical recurrence, especially in cases without seminal vesicle involvement, being low. 10 In patients with positive surgical margins, the likelihood of biochemical recurrence also is relatively low, but such recurrences nonetheless remain a possibility. To date, no patient in the current cohort has developed a biochemical or clinical recurrence; thus, the true biologic significance of the tumors encountered in this contemporary series remains unknown at present. The mechanisms by which prostate carcinoma develops and progresses involve multiple genetic and epigenetic factors, all of which contribute to the heterogeneity of this malignancy. Taking advantage of recent rapid advances in our understanding of the molecular carcinogenesis of prostate carcinoma, new tests may provide information that is useful for screening, detection of disease, staging, and prognosis and that draws further distinction between patients who may benefit from immediate treatment and those who will not. 14,15 In the current analysis, it was found that the 1994 Epstein criteria continued to be useful in the recommendation of treatment options to patients and that these criteria were predictive of extent of disease. In combination with existing nomograms (e.g., Partin tables), these criteria will allow urologists to assess the benefits of treatment on a patient-bypatient basis. In conclusion, the results of the current study of men who underwent radical surgery for clinical T1c disease indicate that insignificant tumors can be found in the majority of patients with prostate carcinoma. In this setting, the 1994 Epstein criteria were found to remain a useful tool in the making of treatment-related decisions. REFERENCES 1. Soh S, Kattan MW, Berkman S, Wheeler M, Sciardino PT. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol. 1997;157: Lerner SE, Seay TM, Blute ML, Bergstralh EJ, Barrett D, Zincke H. Prostate specific antigen detected prostate cancer (clinical Stage T1c): an interim analysis. J Urol. 1996;155: Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95: Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94: Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (Stage T1c) prostate cancer. JAMA. 1994;271: Khan MA, Han M, Partin AW, Epstein JI, Walsh PC. Longterm cancer control of radical prostatectomy in men younger than 50 years of age: update Urology. 2003; 62:86 92.
5 Insignificant Prostate Carcinoma/Bastian et al Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Longterm biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001;28: Epstein JI, Carmichael MJ, Pizov G, Walsh PC. Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J Urol. 1993;150: Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer. 1993;71: Khan MA, Partin AW, Mangold LA, Epstein JI, Walsh PC. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology. 2003;62: Epstein JI, Pound CR, Partin AW, Walsh PC. Disease progression following radical prostatectomy in men with Gleason score 7 tumor. J Urol. 1998;160: de la Taille A, Antiphon P, Salomon L, et al. Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate. Urology. 2003;61: Makhlouf AA, Krupski TL, Kunkle D, Theodorescu D. The effect of sampling more cores on the predictive accuracy of pathological grade and tumor distribution in the prostate biopsy. BJU Int. 2004;93: Nelson WG, DeMarzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349: DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet. 2003; 361:
CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationA NEURAL NETWORK PREDICTS PROGRESSION FOR MEN WITH GLEASON SCORE 3 4 VERSUS 4 3 TUMORS AFTER RADICAL PROSTATECTOMY
ADULT UROLOGY CME ARTICLE A NEURAL NETWORK PREDICTS PROGRESSION FOR MEN WITH GLEASON SCORE 3 4 VERSUS 4 3 TUMORS AFTER RADICAL PROSTATECTOMY MISOP HAN, PETER B. SNOW, JONATHAN I. EPSTEIN, THERESA Y. CHAN,
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationInsignificant Prostate Cancer in Radical Prostatectomy Specimen: TimeTrends and Preoperative Prediction
European Urology European Urology 43 (2003) 455 460 Insignificant Prostate Cancer in Radical Prostatectomy Specimen: TimeTrends and Preoperative Prediction Herbert Augustin a,b, Peter G. Hammerer a,c,*,
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationInformation Content of Five Nomograms for Outcomes in Prostate Cancer
Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:
More informationCorrelation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer
ORIGINAL ARTICLE Correlation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer Teng-Fu Hsieh, Chao-Hsian Chang, Wen-Chi Chen, Chien-Lung
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationProstate Cancer. Axiom. Overdetection Is A Small Issue. Reducing Morbidity and Mortality
Overdetection Is A Small Issue (in the context of decreasing prostate cancer mortality rates and with appropriate, effective, and high-quality treatment) Prostate Cancer Arises silently Dwells in a curable
More informationPrognostic value of the Gleason score in prostate cancer
BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska
More informationPrognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy
Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence
More informationAre Prostate Carcinoma Clinical Stages T1c and T2 Similar?
Clinical Urology Are Clinical Stages T1c and T2 Similar? International Braz J Urol Vol. 32 (2): 165-171, March - April, 2006 Are Prostate Carcinoma Clinical Stages T1c and T2 Similar? Athanase Billis,
More informationInvasion of the muscular wall of the seminal vesicles by prostate cancer is generally
PROSTATE CANCER Seminal Vesicle Invasion by Prostate Cancer: Prognostic Significance and Therapeutic Implications Steven R. Potter, MD,* Jonathan I. Epstein, MD,* Alan W. Partin, MD, PhD* *The James Buchanan
More informationIntroduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer
Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy Premal Patel, MD, 1 Jasmir G. Nayak, MD, 1,2 Zlatica Biljetina, MD, 4 Bryan Donnelly, MD 3, Kiril
More informationCONCLUSIONS. The Epstein Criteria has a suboptimal accuracy for predicting for insignificant prostate cancer.
; 2011 EPSTEIN CRITERIA FOR INSIGNIFICANT PROSTATE CANCER OON ET AL. BJUI Epstein criteria for insignificant prostate cancer Sheng F. Oon*, R. William Watson*, John J. O Leary and John M. Fitzpatrick *Conway
More informationA Nomogram Predicting Long-term Biochemical Recurrence After Radical Prostatectomy
1254 A Nomogram Predicting Long-term Biochemical Recurrence After Radical Prostatectomy Nazareno Suardi, MD 1,2 Christopher R. Porter, MD 3 Alwyn M. Reuther, MD 4 Jochen Walz, MD 1,5 Koichi Kodama, MD
More informationPredictive factors of late biochemical recurrence after radical prostatectomy
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationEvaluation of the 7th American Joint Committee on Cancer TNM Staging System for Prostate Cancer in Point of Classification of Bladder Neck Invasion
Jpn J Clin Oncol 2013;43(2)184 188 doi:10.1093/jjco/hys196 Advance Access Publication 5 December 2012 Evaluation of the 7th American Joint Committee on Cancer TNM Staging System for Prostate Cancer in
More informationRadiation Therapy After Radical Prostatectomy
Articles ISSN 1537-744X; DOI 10.1100/tsw.2004.93 Radiation Therapy After Radical Ali M. Ziada, M.D. and E. David Crawford, M.D. Division of Urology, University of Colorado, Denver, Colorado E-mails: aziada@mednet3.camed.eun.eg
More informationestimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c.
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTION OF AGGRESSIVE RECURRENCE AFTER RP SCHROECK et al. BJUI BJU INTERNATIONAL Do nomograms predict aggressive recurrence after radical
More informationUndergrading and Understaging in Patients with Clinically Insignificant Prostate Cancer who Underwent Radical Prostatectomy
Clinical Urology Clinically Insignificant Prostate Cancer International Braz J Urol Vol. 36 (3): 292-299, May - June, 2010 doi: 10.1590/S1677-55382010000300005 Undergrading and Understaging in Patients
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationPublished Ahead of Print on April 4, 2011 as /JCO J Clin Oncol by American Society of Clinical Oncology INTRODUCTION
Published Ahead of Print on April 4, 2011 as 10.1200/JCO.2010.32.8112 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2010.32.8112 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationPredictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era
ORIGINAL RESEARCH Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era Ahva Shahabi, MPH, PhD; 1* Raj Satkunasivam, MD; 2* Inderbir S. Gill, MD; 2 Gary Lieskovsky,
More informationAlthough the test that measures total prostate-specific antigen (PSA) has been
ORIGINAL ARTICLE STEPHEN LIEBERMAN, MD Chief of Urology Kaiser Permanente Northwest Region Clackamas, OR Effective Clinical Practice. 1999;2:266 271 Can Percent Free Prostate-Specific Antigen Reduce the
More informationAnatomic distribution and pathologic characterization of small-volume prostate cancer (o0.5 ml) in whole-mount prostatectomy specimens
& 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Anatomic distribution and pathologic characterization of small-volume prostate cancer (o0.5 ml) in whole-mount prostatectomy
More informationA Comparative Analysis of Primary and Secondary Gleason Pattern Predictive Ability for Positive Surgical Margins after Radical Prostatectomy
168) Prague Medical Report / Vol. 112 (2011) No. 3, p. 168 176 A Comparative Analysis of Primary and Secondary Gleason Pattern Predictive Ability for Positive Surgical Margins after Radical Prostatectomy
More informationProstate Cancer: Is There Standard Treatment? Who has prostate cancer? In this article:
Focus on CME at l Université de Montréal Prostate Cancer: Is There Standard Treatment? Pierre I. Karakiewicz, MD, FRCSC; Paul Perrotte, MD, FRCSC; Fred Saad, MD, FRCSC In this article: 1. Risk factors
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationChapter 2. Understanding My Diagnosis
Chapter 2. Understanding My Diagnosis With contributions from Nancy L. Brown, Ph.D.,Palo Alto Medical Foundation Research Institute; and Patrick Swift, M.D., Alta Bates Comprehensive Cancer Program o Facts
More informationPercentage of Gleason Pattern 4 and 5 Predicts Survival After Radical Prostatectomy
1967 Percentage of Gleason Pattern 4 and 5 Predicts Survival After Radical Prostatectomy Liang Cheng, MD 1,2 Darrell D. Davidson, MD, PhD 1 Haiqun Lin, MD, PhD 3 Michael O. Koch, MD 2 1 Department of Pathology
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationUse of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence
Cancer Biomarkers 17 (2016) 83 88 83 DOI 10.3233/CBM-160620 IOS Press Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Michael
More informationConceptual basis for active surveillance
Conceptual basis for active surveillance 1. Screening results in overdiagnosis 2. Clinically insignificant disease can be identified 3. All treatments have significant side effects and cost. 4. Delayed
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationApproximately 680,000 men are diagnosed with prostate
Prediction of Indolent Prostate Cancer: Validation and Updating of a Prognostic Nomogram E. W. Steyerberg,* M. J. Roobol, M. W. Kattan, T. H. van der Kwast, H. J. de Koning and F. H. Schröder From the
More informationPREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationThe Role of the Pathologist Active Surveillance for Prostate Cancer
The Role of the Pathologist Active Surveillance for Prostate Cancer Thomas M. Wheeler, M.D. W. L. Moody, Jr., Professor and Chair Department of Pathology & Immunology Baylor College of Medicine Houston,
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationthree after the most recent release in These modifications were based primarily on data from clinical, not pathological, staging [1].
. 2010 BJU INTERNATIONAL Urological Oncology PATHOLOGICAL T2 SUB-DIVISIONS AS A PROGNOSTIC FACTOR IN PROSTATE CANCER CASO ET AL. BJUI BJU INTERNATIONAL Pathological T2 sub-divisions as a prognostic factor
More informationDivision of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC
LHRH AGONISTS: CONTEMPORARY ISSUES The Evolving Definition of Advanced Prostate Cancer Judd W. Moul, MD, FACS Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine,
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationSupplemental Information
Supplemental Information Prediction of Prostate Cancer Recurrence using Quantitative Phase Imaging Shamira Sridharan 1, Virgilia Macias 2, Krishnarao Tangella 3, André Kajdacsy-Balla 2 and Gabriel Popescu
More informationThe Actual Value of the Surgical Margin Status as a Predictor of Disease Progression in Men with Early Prostate Cancer
european urology 50 (2006) 258 265 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer The Actual Value of the Surgical Margin Status as a Predictor of Disease
More informationShort ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy
Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy Sergey Shikanov, Pablo Marchetti, Vikas Desai, Aria Razmaria, Tatjana Antic, Hikmat Al-Ahmadie*, Gregory
More informationEarly outcomes of active surveillance for localized prostate cancer
Original Article ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER HARDIE et al. Early outcomes of active surveillance for localized prostate cancer CLAIRE HARDIE, CHRIS PARKER, ANDREW NORMAN*, ROS EELES,
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationBJUI. Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer
2008 The Authors. Journal compilation 2008 BJU International Original Article TEMPLATE-BASED PROSTATE BIOPSY SYSTEM MEGWALU et al. BJUI BJU INTERNATIONAL Evaluation of a novel precision template-guided
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationPROSTATE BIOPSY: IS AGE IMPORTANT FOR DETERMINING THE PATHOLOGICAL FEATURES IN PROSTATE CANCER?
Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology AGE AND PATHOLOGY OF PROSTATE CA Vol. 31 (4): 331-337, July - August, 2005 PROSTATE BIOPSY: IS AGE IMPORTANT
More informationAre Clinically Insignificant Prostate Cancers Really Insignificant among Korean Men?
Original Article http://dx.doi.org/10.3349/ymj.2012.53.2.358 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 53(2):358-362, 2012 Are Clinically Insignificant Prostate Cancers Really Insignificant among
More informationCorrelation of Preoperative and Radical Prostatectomy Gleason Score: Examining the Predictors of Upgrade and Downgrade Results
ORIGINAL ARTICLE Correlation of Preoperative and Radical Prostatectomy Gleason Score: Examining the Predictors of Upgrade and Downgrade Results Gholamreza Pourmand, Shahram Gooran, Seyed Reza Hossieni,
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationOutcome of Prostate Cancer Patients with Initial PSA I 20 ng/ml Undergoing Radical Prostatectomy
european urology 52 (2007) 1058 1066 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Outcome of Prostate Cancer Patients with Initial PSA I 20 ng/ml Undergoing
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationPCa Commentary. Prostate Cancer? Where's the Meat? - A Collection of Studies Supporting the Safety of Its Use. Seattle Prostate Institute CONTENTS
Volume 70 July - August 2011 PCa Commentary SEATTLE PROSTATE INSTITUTE CONTENTS TESTOSTERONE REPLACEMENT in Hypogonadal Men with Treated and Untreated Prostate Cancer? 1 TESTOSTERONE REPLACEMENT in Hypogonadal
More informationPSA Screening and Prostate Cancer. Rishi Modh, MD
PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University
More informationORIGINAL ARTICLE. Ja Hyeon Ku 1, Kyung Chul Moon 2, Sung Yong Cho 1, Cheol Kwak 1 and Hyeon Hoe Kim 1
(2011) 13, 248 253 ß 2011 AJA, SIMM & SJTU. All rights reserved 1008-682X/11 $32.00 www.nature.com/aja ORIGINAL ARTICLE Serum prostate-specific antigen value adjusted for non-cancerous prostate tissue
More informationDepartment of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara , Japan 2
Advances in Urology Volume 2012, Article ID 204215, 7 pages doi:10.1155/2012/204215 Research Article Calculated Tumor Volume Is an Independent Predictor of Biochemical Recurrence in Patients Who Underwent
More informationOne of the most important clinical applications of
PII S0009-9120(99)00099-5 Clinical Biochemistry, Vol. 33, No. 2, 115 123, 2000 Copyright 2000 The Canadian Society of Clinical Chemists Printed in the USA. All rights reserved 0009-9120/00/$ see front
More informationpt3 Predictive Factors in Patients with a Gleason Score of 6 in Prostate Biopsies
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.9.598 Urological Oncology pt3 Predictive Factors in Patients with a Gleason Score of 6 in Prostate Biopsies Sung Jin Kim, Chang Myon Park, Ki Taek
More informationProstate Cancer Innovations in Surgical Strategies Update 2007!
Prostate Cancer Innovations in Surgical Strategies Update 2007! Curtis A. Pettaway, M.D. Professor Department of Urology The University of Texas M. D. Anderson Cancer Center Radical Prostatectomy Pathologic
More informationMultiinstitutional Validation of the UCSF Cancer of the Prostate Risk Assessment for Prediction of Recurrence After Radical Prostatectomy
2384 Multiinstitutional Validation of the UCSF Cancer of the Prostate Risk Assessment for Prediction of Recurrence After Radical Prostatectomy Matthew R. Cooperberg, MD, MPH 1 Stephen J. Freedland, MD
More informationAccurate prediction of the biological potential of. Correlation between the Gleason Scores of Needle Biopsies and Radical Prostatectomy Specimens
Original Article 919 Correlation between the Gleason Scores of Needle Biopsies and Radical Prostatectomy Specimens Biing-Yir Shen, MD; Ke-Hung Tsui, MD; Phei-Lang Chang, MD; Cheng-Keng Chuang, MD, PHD;
More informationAJCC Cancer Staging 8 th Edition. Prostate Chapter 58. Executive Committee, AJCC. Professor and Director, Duke Prostate Center
AJCC Cancer Staging 8 th Edition Prostate Chapter 58 Judd W Moul, MD, FACS Executive Committee, AJCC Professor and Director, Duke Prostate Center Duke University Durham, North Carolina Validating science.
More informationComparative Analysis Research of Robotic Assisted Laparoscopic Prostatectomy
Comparative Analysis Research of Robotic Assisted Laparoscopic Prostatectomy By: Jonathan Barlaan; Huy Nguyen Mentor: Julio Powsang, MD Reader: Richard Wilder, MD May 2, 211 Abstract Introduction: The
More informationLong-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence
EUROPEAN UROLOGY 59 (2011) 893 899 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Bertrand D. Guillonneau and Karim Fizazi on
More information1. INTRODUCTION. ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7 Abstract:
ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7 www.arcjournals.org Does the Number of Lymph Nodes Removed During Radical Prostatectomy Impact Risk of Biochemical Recurrence in Patients With Isolated
More informationDisease-specific death and metastasis do not occur in patients with Gleason score 6 at radical prostatectomy
Disease-specific death and metastasis do not occur in patients with at radical prostatectomy Charlotte F. Kweldam, Mark F. Wildhagen*, Chris H. Bangma* and Geert J.L.H. van Leenders Departments of Pathology,
More informationHealth Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015
Health Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015 Outline Epidemiology of prostate cancer Purpose of screening Method of screening Contemporary screening trials
More informationElsevier Editorial System(tm) for European Urology Manuscript Draft
Elsevier Editorial System(tm) for European Urology Manuscript Draft Manuscript Number: EURUROL-D-13-00306 Title: Post-Prostatectomy Incontinence and Pelvic Floor Muscle Training: A Defining Problem Article
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationSaturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer
Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2018 Origination: 8/2006 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas
More informationof Nebraska - Lincoln
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln U.S. Department of Veterans Affairs Staff Publications U.S. Department of Veterans Affairs 8-2000 Detection, Characterization,
More informationTHE MOST COMMON definitive therapy for the treatment
Postoperative Nomogram for Disease Recurrence After Radical Prostatectomy for Prostate Cancer Michael W. Kattan, Thomas M. Wheeler, and Peter T. Scardino Purpose: Although models exist that place patients
More informationProstate cancer volume estimations based on transrectal ultrasonography-guided biopsy in order to predict clinically significant prostate cancer
ORIGINAL ARTICLE Vol. 41 (3): 442-448, May - June, 2015 doi: 10.1590/S1677-5538.IBJU.2014.0251 Prostate cancer volume estimations based on transrectal ultrasonography-guided biopsy in order to predict
More informationAUA Update Series. Lesson 33 Volume Active Surveillance for Prostate Cancer: Patient Selection and Management
AUA Update Series Lesson 33 Volume 27 2008 Active Surveillance for Prostate Cancer: Patient Selection and Management Learning Objective: At the conclusion of this continuing medical education activity,
More informationSaturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer
Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2019 Origination: 8/2006 Next Review: 8/2019 Policy Blue Cross and Blue Shield of Kansas
More informationPost Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series
Post Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series E. Z. Neulander 1, K. Rubinov 2, W. Mermershtain 2, Z. Wajsman 3 1 Department of Urology, Soroka
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationProstate-Specific Antigen Testing of Older Men
Prostate-Specific Antigen Testing of Older Men H. Ballentine Carter, Patricia K. Landis, E. Jeffrey Metter, Lee A. Fleisher, Jay D. Pearson Background: Elevated serum prostate-specific antigen (PSA) levels
More informationPredictive criteria of insignificant prostate cancer: what is the correspondence of linear extent to percentage of cancer in a single core?
ORIGINAL ARTICLE Vol. 41 (2): 367-372, March - April, 2015 doi: 10.1590/S1677-5538.IBJU.2015.02.26 Predictive criteria of insignificant prostate cancer: what is the correspondence of linear extent to percentage
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationMEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of
POLICY: PG0367 ORIGINAL EFFECTIVE: 08/26/16 LAST REVIEW: 09/27/18 MEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of Prostate Cancer GUIDELINES This policy does not certify
More informationEvaluation of pt2 subdivisions in the TNM staging system for prostate cancer
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology HONG et al. BJUI BJU INTERNATIONAL Evaluation of pt2 subdivisions in the TNM staging system for prostate cancer Sung Kyu Hong, Byung Kyu
More informationExternal validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer
External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer Mathieu Roumiguié, Jean-Baptiste Beauval, Thomas Filleron*,
More informationInterval from Prostate Biopsy to Robot-Assisted Laparoscopic Radical Prostatectomy (RALP): Effects on Surgical Difficulties
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.10.4 Urological Oncology Interval from Prostate Biopsy to RobotAssisted Laparoscopic Radical Prostatectomy (RALP): Effects on Surgical Difficulties
More informationjournal of medicine The new england Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy abstract
The new england journal of medicine established in 1812 july 8, 4 vol. 31 no. 2 Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy Anthony V. D Amico, M.D.,
More informationincision into an otherwise organ-confined cancer [1,5].
28 The Authors. Journal compilation 28 BJU International Original Article IMPACT ON PROGRESSION OF POSITIVE SURGICAL MARGINS AFTER RP PFITZENMAIER et al. BJUI BJU INTERNATIONAL Positive surgical margins
More informationProstate-specific antigen density as a parameter for the prediction of positive lymph nodes at radical prostatectomy
1 di 10 26/12/2015 17.15 Urol Ann. 2015 Oct-Dec; 7(4): 433 437. doi: 10.4103/0974-7796.152118 PMCID: PMC4660691 Prostate-specific antigen density as a parameter for the prediction of positive lymph nodes
More informationInterval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer
DOI 10.1007/s00345-013-1125-0 ORIGINAL ARTICLE Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer D. M. Bolton A. Ta M. Bagnato
More informationThe utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis
Original Article PREDICTING INSIGNIFICANT PROSTATE CANCER WITH MRI AND CLINICAL VARIABLES SHUKLA-DAVE ET AL. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate
More informationDong Hoon Lee, Ha Bum Jung, Seung Hwan Lee, Koon Ho Rha, Young Deuk Choi, Sung Jun Hong, Seung Choul Yang and Byung Ha Chung *
Jpn J Clin Oncol 2012;42(11)1079 1085 doi:10.1093/jjco/hys147 Advance Access Publication 17 September 2012 Comparison of Pathological Outcomes of Active Surveillance Candidates Who Underwent Radical Prostatectomy
More informationTHE UROLOGY GROUP
THE UROLOGY GROUP www.urologygroupvirginia.com 1860 Town Center Drive Suite 150/160 Reston, VA 20190 703-480-0220 19415 Deerfield Avenue Suite 112 Leesburg, VA 20176 703-724-1195 224-D Cornwall Street,
More informationLocalized Prostate Cancer
T h e n e w e ng l a nd j o u r na l o f m e dic i n e clinical practice Localized Prostate Cancer Patrick C. Walsh, M.D., Theodore L. DeWeese, M.D., and Mario A. Eisenberger, M.D. This Journal feature
More information